Flumazenil subcutaneous - Bexson Biomedical
Alternative Names: BB-20XLatest Information Update: 28 Aug 2026
At a glance
- Originator Bexson Biomedical
- Class Antidotes; Benzodiazepinones; Esters; Fluorine compounds; Imidazoles; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Substance-related disorders
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for preclinical development in Substance-related disorders in USA (SC, Infusion)
- 19 Jul 2022 Preclinical trials in Substance-related disorders in USA (SC)